The first patient has been dosed in the Phase 1 dose-escalation portion of a Phase 1/2 clinical trial evaluating Bicycle Therapeutics’ (NASDAQ:BCYC) BT5528 in patients with EphA2-expressing solid tumors.
BT5528 is a second-generation Bicycle Toxin Conjugate (BTC) that uses a valine-citrulline cleavable linker and a cytotoxin MMAE payload. The company says it has a better safety profile than antibody-drug conjugates.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.